

CONFERENCE PROGRAM

Saturday, May 18

6:30 p.m.–7:30 p.m.

WELCOME AND OPENING KEYNOTE SESSION

Aspen Ballroom

Welcome Remarks

Dan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA

The epigenetics of cancer

Peter A. Jones, Van Andel Research Institute, Grand Rapids, MI

7:30 p.m.–9:30 p.m.

WELCOME RECEPTION

Colorado Ballroom

Sunday, May 19

7:00 a.m.–8:00 a.m.

CONTINENTAL BREAKFAST

Colorado Ballroom

8:00 a.m.–10:00 a.m.

PLENARY SESSION 1: MOLECULAR PATHOLOGY: OMICS, SUBTYPES, BIOMARKERS

Aspen Ballroom

Session Chair: Donna E. Hansel, Oregon Health & Science University, Portland, OR

Molecular subtypes and liquid biopsies for predicting outcome in bladder cancer

Lars Dyrskjøt, Aarhus University Hospital, Aarhus, Denmark

Molecular subtypes of bladder cancer: Toward a more granular description of cancer heterogeneity

David J. McConkey, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD

Molecular alterations in variant morphology

Donna E. Hansel

The shifting landscape of genomics: Impact on clinical decision making

Seth P. Lerner, Baylor College of Medicine, Houston, TX

Novel role of ketone body metabolism in acquired gemcitabine resistance*

Krizia Rohena-Rivera, Cedars-Sinai Medical Center, Los Angeles, CA

10:00 a.m.–10:30 a.m.

BREAK

Aspen Ballroom Foyer

*Short talk from proffered abstract.

- 10:30 a.m.–12:30 p.m.** **PLENARY SESSION 2 AND PANEL DISCUSSION: URINE MOLECULAR DIAGNOSIS**
Aspen Ballroom
- Session Chair: Tahlita C.M. Zuiverloon**, University of Colorado Denver, Aurora, CO
- A urine assay to triage patients with hematuria for cystoscopy**
Joep de Jong, Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
- Potential benefits of and obstacles to use of urine-based tumor markers**
Yair Lotan, UT Southwestern Medical Center, Dallas, TX
- Incorporating proteomics in bladder cancer molecular diagnosis**
Antonia Vlahou, Biomedical Research Foundation Academy of Athens, Athens, Greece
- Profiling intratumoral heterogeneity of bladder cancer subtypes at the single-cell level using machine-learning assisted histopathology***
Andries Zijlstra, Vanderbilt University Medical Center, Nashville, TN
- Panel discussion**
Donna E. Hansel, Yair Lotan, Antonia Vlahou, Joep de Jong
-
- 12:30 p.m.–3:00 p.m.** **POSTER SESSION A / LUNCH**
Colorado Ballroom
-
- 3:00 p.m.–5:00 p.m.** **PLENARY SESSION 3: DRIVERS OF DISEASE: STEM CELLS, MOLECULAR PATHWAYS, TUMOR MICROENVIRONMENT**
Aspen Ballroom
- Session Chair: William Y. Kim**, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
- Collagen microenvironment in the modulation of local invasion and distal metastasis**
Keith S. Chan, Baylor College of Medicine, Houston, TX
- Developing rational combination therapy with checkpoint inhibitors**
Dan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA
- Chemotherapy remodels the bladder cancer immune microenvironment**
William Y. Kim
- Can immunologic biomarkers (CD4/CD8/CD25/CD138) predict tumor recurrence and progression in NMIBC?***
Melinda Lillesand, Stavanger University Hospital, Stavanger, Norway
- Tumor immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes***
Markus Eckstein, University Hospital Erlangen, Erlangen, Germany

**Short talk from proffered abstract.*

CONFERENCE PROGRAM

Monday, May 20

7:00 a.m.–8:00 a.m.

CONTINENTAL BREAKFAST

Colorado Ballroom

8:00 a.m.–10:00 a.m.

PLENARY SESSION 4: BASIC AND TRANSLATIONAL IMMUNO-ONCOLOGY

Aspen Ballroom

Session Chair: Charles G. Drake, Columbia University Medical Center, New York, NY

Basic immunologic mechanisms of PD-1/PD-L1 blockade

Gordon Freeman, Dana-Farber Cancer Institute, Boston, MA

NK cell activation and inactivation in the tumor microenvironment: Potential for mobilizing NK cells for cancer therapy

David H. Raulet, University of California Berkeley, Berkeley, CA

Genetic risk for skin autoimmunity impacts the safety and efficacy of immune checkpoint blockade in urothelial carcinoma

Matthew Albert, insitro, South San Francisco, CA

(not eligible for CME)

Novel immunotherapy combinations for bladder cancer

Charles G. Drake

10:00 a.m.–10:30 a.m.

BREAK

Aspen Ballroom Foyer

10:30 a.m.–12:45 p.m.

PLENARY SESSION 5: MODELS FOR DISCOVERY

Aspen Ballroom

Session Chair: Dan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA

Genetic mouse models and organoids: Synergy for functional genomics of bladder cancer genes

Francisco X. Real, Spanish National Cancer Center (CNIO), Madrid, Spain

Patient-derived organoid models of bladder cancer

Michael M. Shen, Columbia University College of Physicians and Surgeons, New York, NY

Genetic modeling of bladder cancer in the post-genome era

Xue-Ru Wu, NYU School of Medicine, New York, NY

PDX and genetic mouse models for deciphering signaling pathways in bladder cancer

François R. Radvanyi, Institut Curie, Paris, France

Similarities in molecular subtypes and subtype immune patterns between naturally occurring canine and human invasive bladder cancer*

Deborah Knapp, Purdue University, West Lafayette, IN

Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy*

Andrew Hsieh, Fred Hutchinson Cancer Research Center, Seattle, WA

**Short talk from proffered abstract.*

- 12:45 p.m.–3:30 p.m.** **FREE TIME / LUNCH ON OWN**
- 3:30 p.m.–5:00 p.m.** **PLENARY SESSION 6: MANAGEMENT OF NONINVASIVE DISEASE**
Aspen Ballroom
- Session Chair: Peter C. Black**, University of British Columbia, Vancouver, BC, Canada
- Intravesical versus systemic therapy: Win, lose, or draw—the future is now for multidisciplinary NMIBC drug development**
Noah M. Hahn, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
- Intravesical gene therapy for NMIBC**
Colin P.N. Dinney, The University of Texas MD Anderson Center, Houston, TX
- Realizing the potential of targeted therapy in NMIBC**
Peter C. Black
- 5:00 p.m.–7:30 p.m.** **POSTER SESSION B / RECEPTION**
Colorado Ballroom

Tuesday, May 21

- 7:00 a.m.–8:00 a.m.** **CONTINENTAL BREAKFAST**
Colorado Ballroom
- 8:00 a.m.–10:00 a.m.** **PLENARY SESSION 7: NEOADJUVANT AND BLADDER-SPARING APPROACHES TO INVASIVE DISEASE**
Aspen Ballroom
- Session Chair: Jason A. Efstathiou**, Massachusetts General Hospital, Boston, MA
- Recent clinical advances in trimodality therapy including combining immunotherapy with chemoradiation**
Jason A. Efstathiou
- Predictive biomarkers of response to neoadjuvant therapy**
Kent W. Mouw, Dana-Farber Cancer Institute, Boston, MA
- Molecular biomarkers of chemoradiation response in bladder preservation therapy**
David T. Miyamoto, Massachusetts General Hospital, Boston, MA
- Targeting hypoxia and personalizing chemoradiation**
Catharine West, University of Manchester, Manchester, United Kingdom
- Development of a biomarker-based nomogram to predict the pathologic response to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC)***
Andrea Necchi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

**Short talk from proffered abstract.*

CONFERENCE PROGRAM

10:00 a.m.–10:20 a.m.

BREAK

Aspen Ballroom Foyer

10:20 a.m.–12:00 p.m.

PLENARY SESSION 8: MANAGEMENT OF METASTATIC DISEASE

Aspen Ballroom

Session Chair: Dean F. Bajorin, Memorial Sloan Kettering Cancer Center,
New York, NY

New agents in metastatic urothelial carcinoma

Andrea B. Apolo, National Cancer Institute, Bethesda, MD

**Shaping the future of treatment for metastatic disease: Current standards of care and
the clinical trial landscape**

Dean F. Bajorin

The genomic landscape of metastatic urothelial carcinoma from circulating tumor DNA*

Gillian Vandekerkhove, Vancouver Prostate Centre, Vancouver, BC, Canada

**Gene expression profiling in wild-type and mutant FGFR3 metastatic urothelial cancer
treated with combination therapy with vofatamab and pembrolizumab***

Woonyoung Choi, Johns Hopkins School of Medicine, Baltimore, MD

12:00 p.m.

CLOSING REMARKS / DISCUSSION

Aspen Ballroom

**Short talk from proffered abstract.*